Erythrocyte Complement Receptor 1 and Alzheimer Disease
NCT01565434 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200
Last updated 2026-01-21
Summary
Main objective: investigate whether a functional polymorphism of CR1 (length, number of binding sites in C4b C3b, erythrocyte density, rate of soluble CR1 ...) so determined genetic or acquired, is a susceptibility factor for the disease Alzheimer's.
Conditions
- Alzheimer Disease
Interventions
- OTHER
-
CR1 impact
Sponsors & Collaborators
-
CHU de Reims
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- SCREENING
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2012-02-29
- Completion
- 2015-04-30
Countries
- France
Study Locations
More Related Trials
-
A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease
NCT05328115 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate Albumin and Immunoglobulin in Alzheimer's Disease
NCT01561053 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Study to Assess Safety and Target Engagement of E2814 in Participants With Mild to Moderate Cognitive Impairment Due to Dominantly Inherited Alzheimer's Disease
NCT04971733 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Motor Slowing and Its Lesion-related Correlates in Alzheimer's Disease
NCT02811653 ·Status: UNKNOWN ·Phase: NA
-
Efficacy and Safety Study of DCB-AD1 in Patients With Mild to Moderate Alzheimer's Disease
NCT00154635 ·Status: UNKNOWN ·Phase: PHASE2
-
The Clinical Response of Choline Acetyltransferase and Apolipoprotein Epsilon Gene Polymorphisms to Donepezil in Alzheimer's Disease
NCT00381381 ·Status: COMPLETED ·Phase: PHASE4
-
Hyperhomocysteinemia in Alzheimer's Disease
NCT05793372 ·Status: NOT_YET_RECRUITING
-
Study GSI-136 in Healthy Young and Healthy Elderly Subjects
NCT00718731 ·Status: COMPLETED ·Phase: PHASE1
-
Cytokines and Cognitive Decline in Alzheimer's Disease
NCT01351142 ·Status: COMPLETED ·Phase: NA
-
Performance of AclarusDx® a Blood-Based Transcriptomic Test for AD, in French Patients Newly Referred to a Memory Center
NCT02221661 ·Status: COMPLETED
-
A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab
NCT01723826 ·Status: COMPLETED ·Phase: PHASE2
-
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
NCT01561430 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Neuroelectrical Biomarkers for Alzheimer's Disease Stages
NCT01880151 ·Status: COMPLETED ·Phase: NA
-
In Vivo Alzheimer Proteomics
NCT02263235 ·Status: TERMINATED ·Phase: NA
-
A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)
NCT05463731 ·Status: COMPLETED ·Phase: PHASE3
-
Exploratory Clinical Study and Validation of Blood Biomarkers for Alzheimer's Disease
NCT07294586 ·Status: COMPLETED
-
Therapeutic Evaluation of Low-dose IL-2-based Immunomodulatory Approach in Patients With Early AD
NCT05468073 ·Status: RECRUITING ·Phase: PHASE2
-
Safety Of Nrtis for Alzheimer's Therapeutic Advancement in Singapore Study
NCT07210528 ·Status: RECRUITING ·Phase: PHASE1
-
Efficacy and Safety of PRJ212 to Improve the Memory of Patients With Mild Severity Alzheimer's Disease
NCT02991235 ·Status: UNKNOWN ·Phase: NA
-
The Clinical Study of Synaptic Plasticity-based Lencanumab for the Treatment of Early Alzheimer's Disease
NCT06871839 ·Status: RECRUITING
-
Diminishing Accelerated Long-term Forgetting in Mild Cognitive Impairment
NCT05289804 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
An Observational Study on Lecanemab Treatment for Early Alzheimer's Disease
NCT07153848 ·Status: RECRUITING
-
Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment
NCT00149175 ·Status: COMPLETED
-
Marker of Brain Insulin Resistance in AD Prognosis
NCT06825663 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Enhancing Consent for Alzheimer's Research
NCT00453544 ·Status: COMPLETED ·Phase: NA